InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company based in China has announced that the US Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its TYK2 inhibitor, ICP-332. This development marks a significant step forward for the company as it seeks to expand its global footprint.
The TYK2 inhibitor has shown promising results in a Phase II study in China for the treatment of patients with moderate-to-severe atopic dermatitis (AD). The compound has demonstrated exceptional efficacy and a favorable safety profile, achieving multiple efficacy endpoints in the trial. Notably, there is currently no similar product approved globally for the treatment of AD, highlighting the potential impact of ICP-332 on the dermatology market.- Flcube.com
